Literature DB >> 16434671

Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.

F Kimura1, C Fujimura, S Ishida, H Nakajima, D Furutama, H Uehara, K Shinoda, M Sugino, T Hanafusa.   

Abstract

The authors calculated the progression rate (DeltaFS) using the total revised ALS Functional Rating Scale (ALSFRS-R) and symptom duration at diagnosis in 82 Japanese patients with ALS. Survival (death or tracheostomy) differed significantly with the DeltaFS and postdiagnostic period according to log-rank testing, but Cox proportional hazards modeling revealed no strong association between total ALSFRS-R and mortality, suggesting that the DeltaFS provides an additional predictive index beyond ALSFRS-R alone.

Entities:  

Mesh:

Year:  2006        PMID: 16434671     DOI: 10.1212/01.wnl.0000194316.91908.8a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  135 in total

1.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

2.  Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study.

Authors:  Christina Schuster; Elisabeth Kasper; Judith Machts; Daniel Bittner; Jörn Kaufmann; Reiner Benecke; Stefan Teipel; Stefan Vielhaber; Johannes Prudlo
Journal:  J Neurol       Date:  2013-08-31       Impact factor: 4.849

3.  Head injury does not alter disease progression or neuropathologic outcomes in ALS.

Authors:  Christina N Fournier; Marla Gearing; Saila R Upadhyayula; Mitch Klein; Jonathan D Glass
Journal:  Neurology       Date:  2015-04-01       Impact factor: 9.910

4.  Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.

Authors:  Alessandra Gaiani; Ilaria Martinelli; Luca Bello; Giorgia Querin; Marco Puthenparampil; Susanna Ruggero; Elisabetta Toffanin; Annachiara Cagnin; Chiara Briani; Elena Pegoraro; Gianni Sorarù
Journal:  JAMA Neurol       Date:  2017-05-01       Impact factor: 18.302

5.  Metalloproteinase alterations in the bone marrow of ALS patients.

Authors:  Patrizia Bossolasco; Lidia Cova; Cinzia Calzarossa; Federica Servida; Niccolò Emanuele Mencacci; Francesco Onida; Elio Polli; Giorgio Lambertenghi Deliliers; Vincenzo Silani
Journal:  J Mol Med (Berl)       Date:  2010-01-21       Impact factor: 4.599

Review 6.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Altered cortical hubs in functional brain networks in amyotrophic lateral sclerosis.

Authors:  Xujing Ma; Jiuquan Zhang; Youxue Zhang; Heng Chen; Rong Li; Jian Wang; Huafu Chen
Journal:  Neurol Sci       Date:  2015-07-22       Impact factor: 3.307

8.  Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.

Authors:  Antonio Scarafino; Eustachio D'Errico; Alessandro Introna; Angela Fraddosio; Eugenio Distaso; Irene Tempesta; Antonella Morea; Antonella Mastronardi; Rosaria Leante; Maddalena Ruggieri; Mariangela Mastrapasqua; Isabella Laura Simone
Journal:  J Neurol       Date:  2018-08-16       Impact factor: 4.849

9.  Utility of dissociated intrinsic hand muscle atrophy in the diagnosis of amyotrophic lateral sclerosis.

Authors:  Parvathi Menon; Steve Vucic
Journal:  J Vis Exp       Date:  2014-03-04       Impact factor: 1.355

10.  A case of amyotrophic lateral sclerosis with intermediate ATXN-1 CAG repeat expansion in a large family with spinocerebellar ataxia type 1.

Authors:  Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2014-06-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.